These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11102278)

  • 21. Donor leukocyte infusions in myeloid malignancies: new strategies.
    Porter DL; Antin JH
    Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic aspects of blood transfusion.
    Klein HG
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):16-20. PubMed ID: 8202721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical benefits of the leukoreduction of blood products.
    Blajchman MA
    J Trauma; 2006 Jun; 60(6 Suppl):S83-90. PubMed ID: 16763486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic effects of leukocytes present in transfused cellular blood products.
    Bordin JO; Heddle NM; Blajchman MA
    Blood; 1994 Sep; 84(6):1703-21. PubMed ID: 8080981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion.
    Higgins MJ; Blackall DP
    Curr Hematol Rep; 2005 Nov; 4(6):470-6. PubMed ID: 16232385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimum conditions of major histocompatibility complex compatibility and recipient immune compromise required to establish donor white blood cell persistence in a murine transfusion model.
    Lee TH; Wen L; Montalvo L; Esho O; Lowell C; Reed W; Busch M
    Transfusion; 2005 Mar; 45(3):301-14. PubMed ID: 15752147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of two types of leukocyte removal filters on transfusion dependent thalassaemics.
    Jamal R; Mazeni NR; Hussin H
    Malays J Pathol; 2000 Dec; 22(2):79-83. PubMed ID: 16329539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic transplantation for myelodysplastic syndrome (MDS).
    Ingram W; Lim ZY; Mufti GJ
    Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytomegalovirus and blood transfusion].
    Eggen BM
    Tidsskr Nor Laegeforen; 1993 Jan; 113(1):22-4. PubMed ID: 8380944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.
    Loren AW; Porter DL
    Curr Opin Oncol; 2006 Mar; 18(2):107-14. PubMed ID: 16462177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfusion support in liver transplantation.
    Triulzi DJ
    Curr Hematol Rep; 2004 Nov; 3(6):444-9. PubMed ID: 15496279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous white blood cell transfusion: toward a younger immunity.
    Charron D
    Hum Immunol; 2007 Oct; 68(10):805-12. PubMed ID: 17961768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect.
    Alyea EP
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):239-50. PubMed ID: 18503989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apoptosis, TGF beta and transfusion-related immunosuppression: Biologic versus clinical effects.
    Dzik WH
    Transfus Apher Sci; 2003 Oct; 29(2):127-9. PubMed ID: 12941349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Allorecognition of the recipient after hematopoietic transplantation].
    Tiberghien P; Robinet E; Ferrand C; Saas P; Hervé P
    Bull Cancer; 2003; 90(8-9):706-10. PubMed ID: 14609760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfusion-associated graft-versus-host disease.
    Dwyre DM; Holland PV
    Vox Sang; 2008 Aug; 95(2):85-93. PubMed ID: 18544121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Leukocyte depletion of blood products. Indications and technical implementation].
    Böck M; Heim MU
    Fortschr Med; 1995 Mar; 113(8):102-4. PubMed ID: 7759031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Tabayashi T; Yamada K; Takeuchi M
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.